Ácidos graxos ômega 3 e tratamento da esquizofrenia

Detalhes bibliográficos
Autor(a) principal: Zemdegs, Juliane Costa Silva [UNIFESP]
Data de Publicação: 2010
Outros Autores: Pimentel, Gustavo Duarte [UNIFESP], Priel, Margareth Rose
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0101-60832010000500007
http://repositorio.unifesp.br/handle/11600/5579
Resumo: BACKGROUND: Schizophrenia is a complex and debilitating psychiatric disorder, whose primary pharmacological intervention is the use of antipsychotics. There is, however, growing evidence that dietary supplementation with omega 3 fatty acids (n-3) may be beneficial in several psychiatric conditions. OBJECTIVE: To review the efficacy of n-3 as a treatment for schizophrenia. METHODS: Electronic searches of the following databases were performed: Medline, Lilacs e SciELO. The search strategy also included cited reference searching. All relevant randomized controlled trials were included in the review. RESULTS: To date, five out of six randomized, double-blind, and placebo controlled studies obtained improvement in the symptoms of the psychosis. Besides, an advantage in the intake of eicosapentaenoic fatty acid (EPA) in relation to docosahexaenoic fatty acid was designated. Essentially, the intake of 2 g/day of EPA in addition to the standard medication was effective in decreasing the symptoms of schizophrenia. DISCUSSION: The nutritional therapy with EPA revealed to be useful as coadjutant in the treatment of schizophrenia. Therefore, we suggest that the schizophrenic patients should be encouraged to consume balanced and healthy meals rich in EPA and, if the ideal amount is not reached by the diet, the supplementation is likely to be beneficial.
id UFSP_f7210763bd032420f460e03c53488aab
oai_identifier_str oai:repositorio.unifesp.br/:11600/5579
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Ácidos graxos ômega 3 e tratamento da esquizofreniaOmega 3 fatty acid and schizophrenia treatmentSchizophrenianutritioneicosapentaeinoic acidomega 3 fatty acidtreatmentEsquizofrenianutriçãoácido eicosapentaenoicoácido graxo ômega 3tratamentoBACKGROUND: Schizophrenia is a complex and debilitating psychiatric disorder, whose primary pharmacological intervention is the use of antipsychotics. There is, however, growing evidence that dietary supplementation with omega 3 fatty acids (n-3) may be beneficial in several psychiatric conditions. OBJECTIVE: To review the efficacy of n-3 as a treatment for schizophrenia. METHODS: Electronic searches of the following databases were performed: Medline, Lilacs e SciELO. The search strategy also included cited reference searching. All relevant randomized controlled trials were included in the review. RESULTS: To date, five out of six randomized, double-blind, and placebo controlled studies obtained improvement in the symptoms of the psychosis. Besides, an advantage in the intake of eicosapentaenoic fatty acid (EPA) in relation to docosahexaenoic fatty acid was designated. Essentially, the intake of 2 g/day of EPA in addition to the standard medication was effective in decreasing the symptoms of schizophrenia. DISCUSSION: The nutritional therapy with EPA revealed to be useful as coadjutant in the treatment of schizophrenia. Therefore, we suggest that the schizophrenic patients should be encouraged to consume balanced and healthy meals rich in EPA and, if the ideal amount is not reached by the diet, the supplementation is likely to be beneficial.CONTEXTO: A esquizofrenia é uma desordem psiquiátrica complexa e debilitante cujo tratamento de base é realizado com medicamentos antipsicóticos. No entanto, evidências sugerem que a suplementação dietética com ácidos graxos ômega 3 (n-3) pode ser benéfica em diversas desordens psiquiátricas. OBJETIVO: Revisar a eficácia do n-3 como coadjuvante no tratamento farmacológico da esquizofrenia. MÉTODOS: Realizou-se uma pesquisa nas bases de dados eletrônicas Medline, Lilacs e SciELO. A estratégia de busca também incluiu a busca em árvore. Todos os estudos randomizados e controlados relevantes foram incluídos nesta revisão, independentemente do ano de publicação. RESULTADOS: Até o momento, foram divulgados seis estudos randomizados, duplo-cegos placebo controlados; cinco deles apresentaram resultados positivos na melhora dos sintomas da esquizofrenia, assinalando, ainda, superioridade do ácido graxo eicosapentaenoico (EPA) em relação ao ácido graxo docosaexaenoico. Em geral, o consumo de 2 g/dia de EPA conjuntamente com a medicação antipsicótica usual parece reduzir a sintomatologia da esquizofrenia, particularmente os sintomas positivos. CONCLUSÃO: A terapia nutricional com EPA mostrou-se útil como coadjuvante no tratamento da esquizofrenia. Por conseguinte, sugere-se que os pacientes esquizofrênicos sejam encorajados a consumir refeições balanceadas e saudáveis ricas em EPA e, caso a quantidade ideal não seja atingida pela dieta, a suplementação pode ser benéfica.Universidade Federal de São Paulo (UNIFESP) Programa de Pós-Graduação em NutriçãoCentro Universitário São CamiloUNIFESP, Programa de Pós-Graduação em NutriçãoSciELOConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Faculdade de Medicina da Universidade de São PauloUniversidade Federal de São Paulo (UNIFESP)Centro Universitário São CamiloZemdegs, Juliane Costa Silva [UNIFESP]Pimentel, Gustavo Duarte [UNIFESP]Priel, Margareth Rose2015-06-14T13:41:31Z2015-06-14T13:41:31Z2010-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion223-227application/pdfhttp://dx.doi.org/10.1590/S0101-60832010000500007Archives of Clinical Psychiatry. Faculdade de Medicina da Universidade de São Paulo, v. 37, n. 5, p. 223-227, 2010.10.1590/S0101-60832010000500007S0101-60832010000500007.pdf0101-6083S0101-60832010000500007http://repositorio.unifesp.br/handle/11600/5579WOS:000283337900007porArchives of Clinical Psychiatryinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-04T23:49:36Zoai:repositorio.unifesp.br/:11600/5579Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-04T23:49:36Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Ácidos graxos ômega 3 e tratamento da esquizofrenia
Omega 3 fatty acid and schizophrenia treatment
title Ácidos graxos ômega 3 e tratamento da esquizofrenia
spellingShingle Ácidos graxos ômega 3 e tratamento da esquizofrenia
Zemdegs, Juliane Costa Silva [UNIFESP]
Schizophrenia
nutrition
eicosapentaeinoic acid
omega 3 fatty acid
treatment
Esquizofrenia
nutrição
ácido eicosapentaenoico
ácido graxo ômega 3
tratamento
title_short Ácidos graxos ômega 3 e tratamento da esquizofrenia
title_full Ácidos graxos ômega 3 e tratamento da esquizofrenia
title_fullStr Ácidos graxos ômega 3 e tratamento da esquizofrenia
title_full_unstemmed Ácidos graxos ômega 3 e tratamento da esquizofrenia
title_sort Ácidos graxos ômega 3 e tratamento da esquizofrenia
author Zemdegs, Juliane Costa Silva [UNIFESP]
author_facet Zemdegs, Juliane Costa Silva [UNIFESP]
Pimentel, Gustavo Duarte [UNIFESP]
Priel, Margareth Rose
author_role author
author2 Pimentel, Gustavo Duarte [UNIFESP]
Priel, Margareth Rose
author2_role author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
Centro Universitário São Camilo
dc.contributor.author.fl_str_mv Zemdegs, Juliane Costa Silva [UNIFESP]
Pimentel, Gustavo Duarte [UNIFESP]
Priel, Margareth Rose
dc.subject.por.fl_str_mv Schizophrenia
nutrition
eicosapentaeinoic acid
omega 3 fatty acid
treatment
Esquizofrenia
nutrição
ácido eicosapentaenoico
ácido graxo ômega 3
tratamento
topic Schizophrenia
nutrition
eicosapentaeinoic acid
omega 3 fatty acid
treatment
Esquizofrenia
nutrição
ácido eicosapentaenoico
ácido graxo ômega 3
tratamento
description BACKGROUND: Schizophrenia is a complex and debilitating psychiatric disorder, whose primary pharmacological intervention is the use of antipsychotics. There is, however, growing evidence that dietary supplementation with omega 3 fatty acids (n-3) may be beneficial in several psychiatric conditions. OBJECTIVE: To review the efficacy of n-3 as a treatment for schizophrenia. METHODS: Electronic searches of the following databases were performed: Medline, Lilacs e SciELO. The search strategy also included cited reference searching. All relevant randomized controlled trials were included in the review. RESULTS: To date, five out of six randomized, double-blind, and placebo controlled studies obtained improvement in the symptoms of the psychosis. Besides, an advantage in the intake of eicosapentaenoic fatty acid (EPA) in relation to docosahexaenoic fatty acid was designated. Essentially, the intake of 2 g/day of EPA in addition to the standard medication was effective in decreasing the symptoms of schizophrenia. DISCUSSION: The nutritional therapy with EPA revealed to be useful as coadjutant in the treatment of schizophrenia. Therefore, we suggest that the schizophrenic patients should be encouraged to consume balanced and healthy meals rich in EPA and, if the ideal amount is not reached by the diet, the supplementation is likely to be beneficial.
publishDate 2010
dc.date.none.fl_str_mv 2010-01-01
2015-06-14T13:41:31Z
2015-06-14T13:41:31Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0101-60832010000500007
Archives of Clinical Psychiatry. Faculdade de Medicina da Universidade de São Paulo, v. 37, n. 5, p. 223-227, 2010.
10.1590/S0101-60832010000500007
S0101-60832010000500007.pdf
0101-6083
S0101-60832010000500007
http://repositorio.unifesp.br/handle/11600/5579
WOS:000283337900007
url http://dx.doi.org/10.1590/S0101-60832010000500007
http://repositorio.unifesp.br/handle/11600/5579
identifier_str_mv Archives of Clinical Psychiatry. Faculdade de Medicina da Universidade de São Paulo, v. 37, n. 5, p. 223-227, 2010.
10.1590/S0101-60832010000500007
S0101-60832010000500007.pdf
0101-6083
S0101-60832010000500007
WOS:000283337900007
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Archives of Clinical Psychiatry
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 223-227
application/pdf
dc.publisher.none.fl_str_mv Faculdade de Medicina da Universidade de São Paulo
publisher.none.fl_str_mv Faculdade de Medicina da Universidade de São Paulo
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268408999444480